Loading…
← CockpitCompetitor Analysis › DFTX Definium Therapeutics, Inc.Open in the cockpit ↗

Definium Therapeutics, Inc.DFTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.

Momentum neutral 42
Mkt cap
$3.99B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$53.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.2%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$29.12
1D-0.9%
1W-15.5%
1M-17.0%
3M-35.9%
6M+39.5%
YTD+117.5%
1Y+156.8%
ATR %7.0%
Beta1.08
52w lowhigh41.4% off high

What Definium Therapeutics does

Recently listed clinical-stage pharmaceutical company; specific pipeline and disease focus not confidently known.

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech

Moat: none

Employees: 106

Definium Therapeutics at a glance

Size Definium Therapeutics (DFTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.99B, the 1342nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.12 on 18 Nov 2026.

Performance Over six months the shares gained 39.5%, against +0.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Short interest Short interest is 7.2% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026DFTX 129Peer median 103
Six months, rebased to 100: Definium Therapeutics against the median of its 20 peers (local-currency closes).

Definium Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit$0$0-$527,000-$3.16M-$3.22M
EBITDA-$254M-$166M-$103M-$90.7M-$63.1M
Net income-$337M-$184M-$109M-$95.7M-$56.8M
Free cash flow-$189M-$132M-$79.1M-$64.4M-$50.1M
Capital expenditure$0$0$0$0$0
Total debt$36.7M$40.6M$21.9M$14.1M$72,000

Quarterly statements and history in the cockpit →

Definium Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%1289400001004536688336000513600329ROVITARSXENE002294SLSOGNCAMX3320WOCKPHARMADFTX6-month return →1-month return →
Up and to the right = strong over both horizons. Definium Therapeutics is the large dot.

Definium Therapeutics competitors and peer comparison

How Definium Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Definium Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureDFTXPeer medianRank in peer set
1-month return-17.0%+2.6%3rd lowest of 21
6-month return+39.5%+0.8%2nd highest of 20
Distance from 52-week high-41.4%-23.4%5th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%3.3×4.7%+7.5%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%27.6×57.4%+3.1%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%2.3×n/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%2.0×-5.0%+3.2%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%5.5×0.9%+45.1%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%2.3×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%5.1×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%5.8×12.4%+9.7%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
Camurus CAMX.STSweden$4.36B+36%+3%38%16.6×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%3.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%6.5×23.8%+13.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%0.6×-0.7%+4.7%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%

Questions

Which companies are Definium Therapeutics's closest peers?
The cockpit's peer set: HanmiPharm (128940.KS), Novast Laboratories (301569.SZ), Yuhan (000100.KS), Santen Pharmaceutical (4536.T), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), Livzon Pharmaceutical (000513.SZ), Tianjin Pharmaceutical Da Ren Tang (600329.SS), Laboratorios Farmaceuticos Rovi (ROVI.MC).
How has Definium Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +39.5% against +0.8% for the median peer; over one year +156.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.